drugset / Trial / NCT01327573

Eculizumab Therapy for Chronic Complement-Mediated Injury in Kidney Transplantation

NCT01327573

RandomizedParallel-groupOpen-labelTreatment

Summary

This study is designed to assess the effectiveness of eculizumab in recipients of kidney transplantation with donor-specific antibodies (DSA) and worsening kidney function and to assess if eculizumab improves endothelial cell injury in the kidney. The investigators hypothesize that complement inhibition with eculizumab will reduce allograft injury, resulting from less complement-mediated injury of endothelial cells and less endothelial cell activation.

Timeline

Start
2011-03
Primary completion
2015-02
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Eculizumab Monoclonal antibody 900 mg Intravenous

Indications

No indication recorded.